|国家科技期刊平台
首页|期刊导航|中医学报|加味半夏泻心汤联合PPIs降阶梯撤药对非糜烂性反流病寒热错杂证患者生活质量与焦虑抑郁状态的影响

加味半夏泻心汤联合PPIs降阶梯撤药对非糜烂性反流病寒热错杂证患者生活质量与焦虑抑郁状态的影响OACSTPCD

Effect of Modified Banxia Xiexin Decoction and PPIs on Life Quality,Anxiety and Depression with Non-erosive Reflux Disease of Cold and Heat Syndrome

中文摘要英文摘要

目的:观察加味半夏泻心汤联合质子泵抑制剂(proton pump inhibitors,PPIs)降阶梯撤药对非糜烂性反流病(non-erosive reflux disease,NERD)寒热错杂证患者生活质量、焦虑抑郁状态的影响.方法:88 例NERD寒热错杂证患者随机分为观察组46例和对照组42 例.观察组给予加味半夏泻心汤+PPIs降阶梯撤药,对照组予加味半夏泻心汤安慰剂+PPIs降阶梯撤药.比较两组患者治疗前后中医证候疗效,反流与烧心视觉模拟量表(visual analogue scale,VAS)、胃食管反流病健康相关生活质量(GERD health related quality of life,GERD_HRQL)量表、胃食管反流病患者报告结局指标(GERD patient reported outcomes,GERD_PRO)量表、焦虑自评量表(self-rating anxiety scale,SAS)、抑郁自评量表(self-rating depression scale,SDS)评分及不良反应.结果:治疗6 周后,观察组为有效率84.8%(39/46),对照组有效率为64.3%(27/42),两组有效率比较,差异有统计学意义(P<0.05).两组患者治疗2 周、治疗4 周、治疗6 周的烧心VAS评分、SAS评分均低于治疗前,且观察组以上评分低于同期对照组,差异均有统计学意义(P<0.05).两组患者治疗2 周、治疗4 周、治疗6 周的反流与烧心GERD_HRQL量表评分均低于治疗前,且观察组治疗4 周、治疗6 周以上评分均低于同期对照组,差异均有统计学意义(P<0.05).两组患者治疗 2周、治疗4 周、治疗6 周的反流VAS评分、反流与烧心GERD_PRO量表评分、SDS评分均低于治疗前,且观察组治疗 6 周以上评分低于同期对照组,差异均有统计学意义(P<0.05).两组均未出现不良反应.结论:加味半夏泻心汤联合PPIs降阶梯撤药治疗NERD寒热错杂证疗效显著,能够有效改善患者的生活质量与焦虑抑郁状态,且安全性好.

Objective:To observe the effects of modified Banxia Xiexin Decoction combined with proton pump inhibitors(PPIs)on the quality of life,anxiety,and depression of patients with non-erosive reflux disease(NERD)with mixed Cold and Heat syndrome.Meth-od:88 NERD patients with mixed cold and heat syndrome were randomly divided into an observation group of 46 cases and a control group of 42 cases.The observation group was given modified Banxia Xiexin Decoction +PPIs step-down withdrawal,while the control group was given modified Banxia Xiexin Tang placebo +PPIs step-down withdrawal.Compare the therapeutic effects of traditional Chi-nese medicine syndromes before and after treatment between two groups of patients,including the visual analogue scale(VAS)for re-flux and heartburn,the GERD health-related quality of life(GERD_HRQL)scale for gastroesophageal reflux disease,the GERD pa-tient reported outcomes(GERD6RO)scale for gastroesophageal reflux disease,and the self rating anxiety scale(SAS)Self Rating De-pression Scale(SDS)scores and adverse reactions.Results:After 6 weeks of treatment,the observation group had an effective rate of 84.8%(39/46),while the control group had an effective rate of 64.3%(27/42).The difference in effective rates between the two groups was statistically significant(P<0.05).The VAS and SAS scores of the two groups of patients with heartburn after treatment for 2 weeks,4 weeks,and 6 weeks were lower than before treatment,and the observation group had lower scores than the control group dur-ing the same period,with statistical significance(P<0.05).GERD of reflux and heartburn in two groups of patients treated for 2 weeks,4 weeks,and 6 weeks.The HRQL scale scores were lower than before treatment,and the observation group had lower scores than the control group at 4 weeks and above 6 weeks of treatment,with statistical significance(P<0.05).Reflux VAS score,reflux and heartburn GERD of two groups of patients treated for 2 weeks,4 weeks,and 6 weeks.The PRO scale score and SDS score were both low-er than before treatment,and the observation group's score after 6 weeks of treatment was lower than that of the control group during the same period,with statistical significance(P<0.05).Neither group experienced any adverse reactions.Conclusion:The combination of modified Banxia Xiexin Decoction and PPIs step-down withdrawal therapy has a significant therapeutic effect on NERD with mixed Cold and Heat syndrome.It can effectively improve the quality of life and anxiety and depression of patients,with great safety.

万曌;时昭红;张书;刘凡

湖北中医药大学,湖北 武汉 430065湖北中医药大学,湖北 武汉 430065||武汉市中西医结合医院,湖北 武汉 430022武汉市中西医结合医院,湖北 武汉 430022

中医学

非糜烂性反流病加味半夏泻心汤质子泵抑制剂降阶梯撤药生活质量焦虑抑郁状态寒热错杂证

non-erosive reflux diseasemodified Banxia Xiexin Decoctionproton pump inhibitorsstep down withdrawal of medica-tionquality of lifeanxiety and depression statemixed Cold and Heat syndrome

《中医学报》 2024 (002)

406-410 / 5

国家重点研发计划项目(2019YFC1709604);武汉市卫生健康委员会项目(WZ20C03)

10.16368/j.issn.1674-8999.2024.02.067

评论